SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals

Summary

Johnson & Johnson and Pfizer are seeking early-stage cancer assets, with J&J identifying M&A as a strategic priority and Pfizer focusing on Phase 1-2 stage deals. Several biotech companies including Silence Therapeutics, Inhibrx, and Iovance Biotherapeutics are highlighted as potential acquisition targets.